...
search icon
prld-img

Prelude Therapeutics Inc, Common Stock

PRLD

NSQ

$0.97

+$0.02

(2.11%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$53.38M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
168.83K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.55
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.8 L
$6.8 H
$0.97

About Prelude Therapeutics Inc, Common Stock

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware. more

Industry: BiotechnologySector: Health Care

Returns

Time FramePRLDSectorS&P500
1-Week Return-3.96%-0.03%1.53%
1-Month Return-4.9%4.56%4.75%
3-Month Return-5.83%1.29%2.77%
6-Month Return-81.2%-3.54%12.18%
1-Year Return-71.3%1.59%22.34%
3-Year Return-90.08%13.55%38.91%
5-Year Return-96.3%40.85%80.7%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue382.00K542.00K2.24M3.04M1.17M[{"date":"2019-12-31","value":12.56,"profit":true},{"date":"2020-12-31","value":17.82,"profit":true},{"date":"2021-12-31","value":73.73,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":38.43,"profit":true}]
Gross Profit(382.00K)(542.00K)(2.24M)(3.04M)(1.17M)[{"date":"2019-12-31","value":-38200000,"profit":false},{"date":"2020-12-31","value":-54200000,"profit":false},{"date":"2021-12-31","value":-224300000,"profit":false},{"date":"2022-12-31","value":-304200000,"profit":false},{"date":"2023-12-31","value":-116900000,"profit":false}]
Gross Margin(Infinity%)(Infinity%)(Infinity%)(Infinity%)(Infinity%)[{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}]
Operating Expenses28.11M58.76M113.73M123.54M132.28M[{"date":"2019-12-31","value":21.25,"profit":true},{"date":"2020-12-31","value":44.42,"profit":true},{"date":"2021-12-31","value":85.98,"profit":true},{"date":"2022-12-31","value":93.39,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(28.11M)(58.76M)(113.73M)(123.54M)(132.28M)[{"date":"2019-12-31","value":-2810900000,"profit":false},{"date":"2020-12-31","value":-5876300000,"profit":false},{"date":"2021-12-31","value":-11373500000,"profit":false},{"date":"2022-12-31","value":-12354000000,"profit":false},{"date":"2023-12-31","value":-13227700000,"profit":false}]
Total Non-Operating Income/Expense-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Pre-Tax Income(27.57M)(56.93M)(111.69M)(115.44M)(121.83M)[{"date":"2019-12-31","value":-2757000000,"profit":false},{"date":"2020-12-31","value":-5692900000,"profit":false},{"date":"2021-12-31","value":-11169400000,"profit":false},{"date":"2022-12-31","value":-11543800000,"profit":false},{"date":"2023-12-31","value":-12183200000,"profit":false}]
Income Taxes(539.00K)335.70K(915.00K)(8.10M)(1.00)[{"date":"2019-12-31","value":-160.56,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-272.56,"profit":false},{"date":"2022-12-31","value":-2413.44,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Income After Taxes-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Income From Continuous Operations(27.57M)(56.93M)(111.69M)(115.44M)(117.40M)[{"date":"2019-12-31","value":-2757000000,"profit":false},{"date":"2020-12-31","value":-5692900000,"profit":false},{"date":"2021-12-31","value":-11169400000,"profit":false},{"date":"2022-12-31","value":-11543800000,"profit":false},{"date":"2023-12-31","value":-11739800000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(27.57M)(56.93M)(110.78M)(107.34M)(121.83M)[{"date":"2019-12-31","value":-2757000000,"profit":false},{"date":"2020-12-31","value":-5692900000,"profit":false},{"date":"2021-12-31","value":-11077900000,"profit":false},{"date":"2022-12-31","value":-10733600000,"profit":false},{"date":"2023-12-31","value":-12183200000,"profit":false}]
EPS (Diluted)-(11.20)(2.42)(2.44)(2.03)[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-1120,"profit":false},{"date":"2021-12-31","value":-242,"profit":false},{"date":"2022-12-31","value":-244,"profit":false},{"date":"2023-12-31","value":-203,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

PRLD
Cash Ratio 6.91
Current Ratio 7.04

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

PRLD
ROA (LTM) -39.29%
ROE (LTM) -66.64%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

PRLD
Debt Ratio Lower is generally better. Negative is bad. 0.21
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.79

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

PRLD
Trailing PE NM
Forward PE NM
P/S (TTM) 17.79
P/B 0.34
Price/FCF NM
EV/R 0.00
EV/Ebitda NM

FAQs

What is Prelude Therapeutics Inc share price today?

Prelude Therapeutics Inc (PRLD) share price today is $0.97

Can Indians buy Prelude Therapeutics Inc shares?

Yes, Indians can buy shares of Prelude Therapeutics Inc (PRLD) on Vested. To buy Prelude Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in PRLD stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Prelude Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Prelude Therapeutics Inc (PRLD) via the Vested app. You can start investing in Prelude Therapeutics Inc (PRLD) with a minimum investment of $1.

How to invest in Prelude Therapeutics Inc shares from India?

You can invest in shares of Prelude Therapeutics Inc (PRLD) via Vested in three simple steps:

  • Click on Sign Up or Invest in PRLD stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Prelude Therapeutics Inc shares
What is Prelude Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Prelude Therapeutics Inc (PRLD) is $6.8. The 52-week low price of Prelude Therapeutics Inc (PRLD) is $0.8.

What is Prelude Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Prelude Therapeutics Inc (PRLD) is 0.34

What is the Market Cap of Prelude Therapeutics Inc?

The market capitalization of Prelude Therapeutics Inc (PRLD) is $53.38M

What is Prelude Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Prelude Therapeutics Inc is PRLD

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top